Blueprint Medicines (BPMC) Misses Q1 EPS by 8c

Blueprint Medicines (NASDAQ: BPMC) reported Q1 EPS of ($0.84), $0.08 worse than the analyst estimate of ($0.76).

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• AeroVironment restates quarterly financials, citing $89M goodwill error
• Ridgepost Capital acquires Stellus Capital Management for $4B AUM